Q-omics provides the consensus-scored GID8 profile across patient tissues and cancer cell-line models. GID8 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GID8 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, GID8 protein abundance shows 27,110 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where GID8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GID8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GID8 survival associations across molecular data types. GID8 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GID8 RNA expression–survival associations across cancer types. High GID8 expression shows unfavorable associations in ACC, LIHC, BLCA and UCEC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GID8 RNA expression.
This table summarizes GID8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 12. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GID8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GID8 shows higher tumor expression in COAD, LUSC, LIHC, BLCA, LUAD and STAD. The COAD box plot shows higher GID8 RNA expression in tumor versus normal tissue (log2 FC = +0.896, t-test p < 0.001).
This table shows molecular features associated with GID8 in patient tissues and cancer cell lines. In patient samples, GID8 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GID8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
